ISSUE 1465
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Tiotropium bromide, an inhaled long-acting anticholinergic available since 2004 as a dry powder inhaler (Spiriva Handihaler) for once-daily treatment of chronic obstructive pulmonary disease (COPD),1 has now also been approved in an inhalation spray formulation (Spiriva Respimat – Boehringer Ingelheim). According to the manufacturer, the Respimat device improves delivery of tiotropium to the lungs because, unlike with the Handihaler, it is not dependent on the strength of the patient's breath intake.
MAINTENANCE TREATMENT – In patients with moderate to severe COPD, regular treatment with an inhaled long-acting bronchodilator (an anticholinergic or a beta2-agonist) can relieve symptoms, improve lung function, and reduce the frequency of exacerbations. A combination of an anticholinergic and a beta2-agonist can be used for
... more- Tiotropium (Spiriva) for COPD. Med Lett Drugs Ther 2004; 46:41.
- Drugs for asthma and COPD. Treat Guidel Med Lett 2013; 11:75.
- E Bateman et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010; 5:197.
- ED Bateman et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med 2010; 104:1460.
- DP Tashkin et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543.
- RA Wise et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369:1491.

Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1465e
Electronic, downloadable article - $45